London Co. of Virginia purchased a new position in Astrazeneca Plc (NYSE:AZN – Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 6,470 shares of the company’s stock, valued at approximately $1,276,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of AZN. Cumberland Partners Ltd increased its holdings in shares of Astrazeneca by 16.2% in the 1st quarter. Cumberland Partners Ltd now owns 145,746 shares of the company’s stock valued at $28,744,000 after acquiring an additional 20,334 shares during the last quarter. Public Employees Retirement System of Ohio lifted its stake in Astrazeneca by 242.6% during the first quarter. Public Employees Retirement System of Ohio now owns 957,000 shares of the company’s stock worth $186,144,000 after purchasing an additional 677,700 shares during the last quarter. Keebeck Wealth Management bought a new position in Astrazeneca during the first quarter worth $237,000. Aureus Asset Management LLC acquired a new position in Astrazeneca in the first quarter worth $218,000. Finally, Clal Insurance Enterprises Holdings Ltd boosted its holdings in Astrazeneca by 51.8% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 258 shares of the company’s stock worth $50,000 after purchasing an additional 88 shares during the period. 20.35% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. HSBC cut shares of Astrazeneca from a “buy” rating to a “hold” rating in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Finally, Barclays reissued a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $211.00.
Astrazeneca Stock Down 0.3%
NYSE AZN opened at $168.68 on Monday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The company’s 50 day simple moving average is $180.55 and its 200 day simple moving average is $188.07. Astrazeneca Plc has a 12 month low of $142.98 and a 12 month high of $212.71. The company has a market capitalization of $261.61 billion, a P/E ratio of 25.33, a PEG ratio of 1.38 and a beta of 0.24.
Astrazeneca (NYSE:AZN – Get Free Report) last released its earnings results on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, topping the consensus estimate of $2.10 by $0.53. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The business had revenue of $15.38 billion for the quarter, compared to the consensus estimate of $15.44 billion. Equities research analysts expect that Astrazeneca Plc will post 10.22 earnings per share for the current fiscal year.
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
- Five stocks we like better than Astrazeneca
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
